Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report

Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD‐1) inhibitors have been reported to show antitumor effects in patients with high programmed death‐ligand 1 (PD‐L1) expressing SC, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Taniguchi, Hirokazu, Takemoto, Shinnosuke, Ozasa, Mutsumi, Honda, Noritaka, Suyama, Takayuki, Umeyama, Yasuhiro, Dotsu, Yosuke, Nakao, Takumi, Tomohito, Kojima, Gyotoku, Hiroshi, Yamaguchi, Hiroyuki, Miyazaki, Taiga, Sakamoto, Noriho, Obase, Yasushi, Fukuda, Minoru, Fukuoka, Junya, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017259/
https://www.ncbi.nlm.nih.gov/pubmed/33605089
http://dx.doi.org/10.1111/1759-7714.13890
Descripción
Sumario:Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD‐1) inhibitors have been reported to show antitumor effects in patients with high programmed death‐ligand 1 (PD‐L1) expressing SC, the efficacy of combined therapy with PD‐1 inhibitor plus cytotoxic chemotherapy has not previously been clarified. We herein report a case of SC with low expression of PD‐L1 and few pre‐existing tumor‐infiltrating lymphocytes which showed a remarkable response to pembrolizumab plus cytotoxic chemotherapy as first‐line treatment. Our findings suggest that combined treatment might enhance the immunogenic response, even in immunologically ignored SCs.

Ejemplares similares